Business Wire

LR-HEALTH-&-BEAUTY

18.6.2020 17:49:09 CEST | Business Wire | Press release

Share
Awarded – LR is the Winner of the German Brand Award Once Again

Today, the LR LIFETAKT NIGHT MASTER product was awarded the German Brand Award 2020. This is a sensational success for the LR Health & Beauty company, which launched a new segment in its health portfolio with this sleep drink.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200618005674/en/

In the “Excellent Brands” competition, the vegan, holistically designed product impressed the jury in the “Health & Pharmaceuticals” category as one of the best product brands in the industry. The nightcap also received a “Special Mention” in the cross-industry category “Product Brand of the Year”, in which the jury awards a prize for special aspects of brand management. The German Brand Institute already distinguished LR as a winner in 2019 in the “Beauty & Care” category for its 5in1 Beauty Elixir product.

“The second award in a row for an advanced product development makes me and makes us all, incredibly proud and happy, and highlights our expertise in the health field,” says Andreas Friesch, CEO of LR Health & Beauty. “True to the company motto ‘More quality for your life’, we have developed a natural, effective, non-addictive product that is in touch with today’s trends*. Receiving recognition for this motivates us to keep developing innovative product solutions in the future,” Friesch says.

The secret of healthy sleep: LR LIFETAKT NIGHT MASTER

Healthy sleep improves quality of life, strengthens the immune system and heightens performance. Sleep is a desperate challenge for many but it does not have to be.*

The NIGHT MASTER sleep drink from LR LIFETAKT is an effective dietary supplement that ensures a restful sleep over the long term, in a healthy way that is non-addictive. Natural and scientifically proven active ingredients like hops and saffron extract, aloe vera, the amino acid L-tryptophan, magnesium and zinc, as well as a vitamin B complex distinguish the highly bioavailable formula. With its threefold effect, the product promotes relaxation when falling asleep and relaxation while sleeping through the night, as well as optimized regeneration. The product is vegan and it is gluten, lactose and sugar free. www.LRNightMaster.com

German Brand Award | German Design Council
The German Brand Award is a competition presented by the German Brand Institute. The Institute was founded by the German Design Council (Rat für Formgebung) in order to strengthen brand management as a crucial factor for success in companies in the national and international competitive field. It is a driving force of German brand economy, bringing together major brand-builders and stimulating brand dialog. The German Brand Award presented by the Institute is one of the most notable German brand awards.

The German Design Council is an independent and internationally active institution that supports companies in efficiently communicating design and brand competence, while at the same time aiming to strengthen design awareness among the general public. More information at: german-brand-award.com

LR Health & Beauty
Under the motto “More quality for your life”, the LR Group of Companies, with headquarters in the German city of Ahlen, markets diverse beauty and health products in 28 different countries. These include skin care and color cosmetics, dietary supplements and fragrances. LR Health & Beauty has made it its goal to improve the well-being and health of people through its product portfolio. That is why the company keeps developing new products – from the forces of nature combined with the latest scientific discoveries. Aloe Vera has been one of LR's key competences for over 18 years, where we only use the precious leaf fillet is used. With approximately 1,200 employees and thousands of registered sales partners and customers, LR is one of the leading direct sales companies in Europe. The company has been assisting children in need and their families in various countries around the world through the LR Global Kids Fund e.V. – in a fast and non-bureaucratic way in cooperation with local established institutions.

*78% of Germans suffer from sleep problems, according to a nationwide CATI-representative survey conducted by Mente>factum on behalf of LR in 2019

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 07:30:00 CET | Press release

Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob

Invivoscribe® Launches LeukoStrat® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 06:30:00 CET | Press release

Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan

VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 01:00:00 CET | Press release

Enabling Next-Generation High-Performance Automotive Camera Systems VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise

Kinaxis Inc. to Host Fourth Quarter 2025 Financial Results Conference Call on March 5, 20264.2.2026 22:30:00 CET | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in supply chain orchestration, today announced that it has scheduled its conference call to discuss the financial results for its fourth quarter and year ended December 31, 2025. The call will be hosted on Thursday, March 5 at 8:30 a.m. Eastern Time by Razat Gaurav, chief executive officer, and Blaine Fitzgerald, chief financial officer, followed by a question and answer period. The Company will report its financial results for the fourth quarter and year after the close of markets on Wednesday, March 4, 2026. CONFERENCE CALL DETAILS DATE: Thursday, March 5, 2026 TIME: 8:30 a.m. Eastern Time WEBCAST: https://events.q4inc.com/attendee/567578009 (available for three months) About Kinaxis Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that

Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 22:30:00 CET | Press release

Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye